JP6007101B2 - 手足皮膚反応治療のためのアロプリノールの使用 - Google Patents

手足皮膚反応治療のためのアロプリノールの使用 Download PDF

Info

Publication number
JP6007101B2
JP6007101B2 JP2012507765A JP2012507765A JP6007101B2 JP 6007101 B2 JP6007101 B2 JP 6007101B2 JP 2012507765 A JP2012507765 A JP 2012507765A JP 2012507765 A JP2012507765 A JP 2012507765A JP 6007101 B2 JP6007101 B2 JP 6007101B2
Authority
JP
Japan
Prior art keywords
allopurinol
treatment
hfsr
medicament
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012507765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525358A (ja
JP2012525358A5 (cg-RX-API-DMAC7.html
Inventor
ローデメール、ヨランダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advancell Advanced In Vitro Cell Technologies SA
Original Assignee
Advancell Advanced In Vitro Cell Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advancell Advanced In Vitro Cell Technologies SA filed Critical Advancell Advanced In Vitro Cell Technologies SA
Publication of JP2012525358A publication Critical patent/JP2012525358A/ja
Publication of JP2012525358A5 publication Critical patent/JP2012525358A5/ja
Application granted granted Critical
Publication of JP6007101B2 publication Critical patent/JP6007101B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012507765A 2009-04-29 2010-04-29 手足皮膚反応治療のためのアロプリノールの使用 Expired - Fee Related JP6007101B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
US61/214,894 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
EP09382058.7 2009-04-29
PCT/EP2010/055806 WO2010125143A1 (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (3)

Publication Number Publication Date
JP2012525358A JP2012525358A (ja) 2012-10-22
JP2012525358A5 JP2012525358A5 (cg-RX-API-DMAC7.html) 2014-12-11
JP6007101B2 true JP6007101B2 (ja) 2016-10-12

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507765A Expired - Fee Related JP6007101B2 (ja) 2009-04-29 2010-04-29 手足皮膚反応治療のためのアロプリノールの使用

Country Status (22)

Country Link
US (2) US8623878B2 (cg-RX-API-DMAC7.html)
EP (2) EP2246057A1 (cg-RX-API-DMAC7.html)
JP (1) JP6007101B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120049848A (cg-RX-API-DMAC7.html)
CN (1) CN102421436B (cg-RX-API-DMAC7.html)
AR (1) AR076505A1 (cg-RX-API-DMAC7.html)
AU (2) AU2010243594A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1011971A2 (cg-RX-API-DMAC7.html)
CA (1) CA2759085C (cg-RX-API-DMAC7.html)
DK (1) DK2424538T3 (cg-RX-API-DMAC7.html)
ES (1) ES2434366T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20131070T1 (cg-RX-API-DMAC7.html)
IL (1) IL215831A (cg-RX-API-DMAC7.html)
ME (1) ME01567B (cg-RX-API-DMAC7.html)
MX (1) MX2011011529A (cg-RX-API-DMAC7.html)
NZ (1) NZ595901A (cg-RX-API-DMAC7.html)
PL (1) PL2424538T3 (cg-RX-API-DMAC7.html)
PT (1) PT2424538E (cg-RX-API-DMAC7.html)
RS (1) RS53005B (cg-RX-API-DMAC7.html)
RU (1) RU2543325C2 (cg-RX-API-DMAC7.html)
SI (1) SI2424538T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010125143A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220713B2 (en) 2009-10-16 2015-12-29 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
JP2014502998A (ja) * 2011-01-18 2014-02-06 ビカス セラピューティクス，エルエルシー 薬学的組成物ならびに薬学的組成物を作製および使用するための方法
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
WO2019201195A1 (zh) 2018-04-16 2019-10-24 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
CA3242908A1 (en) 2022-01-05 2023-07-13 Asymmetric Therapeutics, Llc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE SKIN DISORDERS AND OTHER SKIN CONDITIONS
KR20250056445A (ko) * 2023-10-19 2025-04-28 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0278040B1 (de) 1987-02-13 1991-08-14 Pharm-Allergan Gmbh Verwendung von Pteridinen und/oder Purinen oder eines Xanthinoxidase-Hemmers zur Herstellung eines Arzneimittels zur Behandlung von genetisch bedingten degenerativen Netzhauterkrankungen
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
DE60117043T2 (de) 2000-11-22 2006-07-13 Rxkinetix, Inc., Louisville Behandlung von mukositis
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
ATE429947T1 (de) 2001-08-29 2009-05-15 Pharmakodex Ltd Vorrichtung zur topischen verabreichung
KR100949318B1 (ko) 2001-11-29 2010-03-23 사운드 파마슈티칼스 인코퍼레이티드 화학요법의 바람직하지 않은 작용을 개선하기 위한 방법과조성물
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
EP1631146A4 (en) 2003-06-11 2006-12-06 Novacea Inc TREATMENT OF CANCER USING ACTIVE VITAMIN COMPOUNDS ASSOCIATED WITH RADIOTHERAPEUTIC AGENTS AND TREATMENTS
EP1631297A4 (en) 2003-06-11 2007-09-05 Novacea Inc TREATMENT OF IMMUNOSTIC DISEASES WITH ACTIVE VITAMIN D COMPOUNDS ALONE OR IN COMBINATION WITH OTHER THERAPEUTICS
US20050148907A1 (en) 2003-12-24 2005-07-07 Gregory Skover Treatment of skin using a benefit agent and an apparatus
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
PT1796660T (pt) 2004-09-17 2017-02-13 Biomas Ltd Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta
DE602007004849D1 (de) 2006-06-01 2010-04-01 Nobera Pharma Sl Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie

Also Published As

Publication number Publication date
AU2016228193A1 (en) 2016-11-03
CA2759085C (en) 2016-08-16
US8623878B2 (en) 2014-01-07
PL2424538T3 (pl) 2014-05-30
CN102421436A (zh) 2012-04-18
CN102421436B (zh) 2014-05-07
BRPI1011971A2 (pt) 2016-04-26
IL215831A (en) 2016-02-29
IL215831A0 (en) 2012-01-31
US20140080845A1 (en) 2014-03-20
EP2246057A1 (en) 2010-11-03
JP2012525358A (ja) 2012-10-22
MX2011011529A (es) 2012-02-08
ME01567B (me) 2014-04-20
EP2424538A1 (en) 2012-03-07
RS53005B (sr) 2014-04-30
DK2424538T3 (da) 2013-11-04
ES2434366T3 (es) 2013-12-16
HK1168042A1 (en) 2012-12-21
EP2424538B1 (en) 2013-08-14
SI2424538T1 (sl) 2013-12-31
HRP20131070T1 (hr) 2013-12-20
PT2424538E (pt) 2013-11-07
NZ595901A (en) 2013-11-29
AU2010243594A1 (en) 2011-11-10
CA2759085A1 (en) 2010-11-04
WO2010125143A1 (en) 2010-11-04
RU2011148355A (ru) 2013-06-10
AR076505A1 (es) 2011-06-15
RU2543325C2 (ru) 2015-02-27
US20100280051A1 (en) 2010-11-04
KR20120049848A (ko) 2012-05-17

Similar Documents

Publication Publication Date Title
JP5028480B2 (ja) 手足症候群の治療のためのアロプリノールの使用
JP6007101B2 (ja) 手足皮膚反応治療のためのアロプリノールの使用
CN101460172B (zh) 别嘌醇在制备治疗手足综合征的药物中的用途
HK1168042B (en) Use of allopurinol for the treatment of hand foot skin reaction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140702

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141015

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20141015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160912

R150 Certificate of patent or registration of utility model

Ref document number: 6007101

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees